About
Dr. Roy D. Baynes has served on Aardvark's Board since December 2024. Since July 2022 he has been Executive Vice President and Chief Medical Officer of Eikon Therapeutics, Inc. (Nasdaq: EIKN). He previously served as Senior Vice President and Head of Global Clinical Development at Merck Research Laboratories from 2013 and as Chief Medical Officer of Merck & Co. from 2016 until April 2022, and earlier led therapeutic areas at Gilead Sciences and Amgen. He has authored more than 150 publications. Dr. Baynes received his medical degree and Ph.D. from the University of the Witwatersrand in South Africa. He serves on Aardvark's Nominating and Corporate Governance and Compensation Committees.
Roles
Aardvark Therapeutics, Inc.
Director · Current role
December 2024–present
Eikon Therapeutics, Inc.
Executive Vice President & Chief Medical Officer
2022 - present
Merck & Co., Inc.
Chief Medical Officer
2016 - 2022
Merck Research Laboratories
Senior Vice President & Head of Global Clinical Development
2013 - 2022
Gilead Sciences, Inc.
Senior Vice President, Oncology, Inflammation and Respiratory Therapeutics
2012 - 2013
Amgen Inc.
Vice President, Global Clinical Development; Therapeutic Area Head, Hematology/Oncology
—
External Roles
Travere Therapeutics Inc.
Director
2016 - present
Nurix Therapeutics, Inc.
Director
2025 - present
Atara Biotherapeutics, Inc.
Director
2018 - 2022
Director Compensation
FY 2025
Fees earned or paid in cash
$48,374
Also at Aardvark Therapeutics, Inc.